Peacock Tariff Consulting works with Danish pharma exporters (Novo Nordisk-scale firms, Lundbeck, Leo Pharma), medtech (Coloplast, William Demant), Maersk-adjacent shipping, and Danish dairy/pork exporters. Novo Nordisk alone makes Denmark one of the most tariff-sensitive countries in Europe.
Novo Nordisk alone makes Denmark one of the most tariff-sensitive countries in Europe – any Section 232 pharma decision dramatically changes their U.S. cost curve. Maersk decisions shape global shipping flows. Danish medtech (Coloplast, William Demant) and agri-food (dairy, pork) add further verticals.
Peacock Tariff Consulting works with Danish exporters across these clusters.
Novo Nordisk-scale pharma 232 scenarios
Novo Nordisk’s GLP-1 portfolio (Ozempic, Wegovy) faces direct Section 232 pharma exposure on entry to the U.S. Generics and biosimilars excluded; branded patented drugs covered. For Novo and similar Danish pharma exporters, scenario modeling drives strategic decisions.
Danish MedTech 232 probe readiness
Coloplast, William Demant, and Danish MedTech generally face the parallel Section 232 MedTech probe. Scope and rate determination remain pending.
Danish dairy U.S. reciprocal exposure
Danish dairy exports face base MFN plus Section 122. Specialty dairy products (Havarti, butter) have specific HTS classifications.
Maersk-perspective: global routing under tariff shifts
Maersk’s perspective on global shipping informs how multinational shippers think about tariff routing. While we do not advise Maersk directly, the shipping-flow perspective is part of the Copenhagen-area context.
Wind component AD/CVD for Danish exporters
Danish wind energy component exports (Vestas adjacencies) face U.S. AD/CVD scrutiny. Scope rulings matter for specific products.
Frequently asked questions
Do you work with Novo Nordisk-scale pharma firms?
Yes. Section 232 pharma scenario modeling for Danish pharma is one of our active engagement profiles for the Copenhagen market.
How does Section 232 pharma affect Novo Nordisk?
Branded patented drugs from Novo Nordisk face the new tariff effective July 31, 2026 with tiered rates. The rate exposure on Ozempic, Wegovy, and similar high-value products is significant.
Can you handle Vestas wind component AD/CVD?
Yes. AD/CVD scope rulings on Danish wind components are an area we cover.
What about Danish dairy?
Danish dairy classification, origin, and Section 122 exposure modeling – yes, we cover these.
Are you affiliated with Dansk Industri or Lif?
No. We are independent.
Get started
Book a Danish exporter U.S. tariff review.